(CercleFinance.com) – Nicox reduced its losses last year, but also saw its turnover and its cash dwindle, a trend which weighed on the share price of the pharmaceutical company Monday morning in Paris.
In the 2022 financial year, the laboratory specializing in ophthalmology recorded a net loss of 27.8 million euros, compared to 43.8 million a year earlier.
Its annual net turnover totaled 3.3 million euros, entirely made up of net royalties, compared to 7.2 million (mainly milestone payments in the context of partnerships) in 2021.
Nicox generates most of its revenue from Vyzulta, which is licensed exclusively worldwide to its partner Bausch + Lomb, which has seen sales growth of 31% as well as an increase in the number of prescriptions in the United States.
As of December 31, 2022, its cash position represented 27.7 million euros compared to 42 million a year earlier, an amount that the company considers sufficient to ensure its financing until the second quarter of 2024, exclusively on the basis of the development of the NCX 470 .
While the results of the Mont Blanc study on NCX 470 are already known, those of the phase 3 clinical trial in open-angle glaucoma or ocular hypertension are not expected before 2025.
Following these announcements, the Nicox share lost 0.9%, bringing out a market capitalization of 33.3 million euros.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
